Category: McKesson Corp.
A federal judge dismisses a whistleblower lawsuit accusing McKesson of encouraging Medicare fraud and getting rid of workers who opposed the scheme.
San Francisco-based healthcare giant McKesson (NYSE:MCK) dodged a Medicare fraud lawsuit this week after a federal judge ruled that prospective whistleblower Leslie Ann Williams didn't have enough evidence to support her accusations.
McKesson Technologies recalls its anesthesia care system over a potential software glitch that mismatched patient case data with patient data.
Updated March 20, 2014, at 3:15 p.m. with comments from McKesson
The White House has let half of the Affordable Care Act's mandatory deadlines slip by, according to a report by the non-partisan Congressional Research Service.
MASSDEVICE ON CALL — During the 1st 3 years of Affordable Care Act implementation, the Obama administration has failed to meet half of its mandatory deadlines, according to a new report from the non-partisan Congressional Research Service.
Abbott and Johnson & Johnson are among the U.S.-based companies that park billions in offshore tax havens, according to a U.S. PIRG report.
Abbott (NYSE:ABT) parked some $40 billion in 107 overseas tax havens last year, making it 1 of the top 15 U.S. companies with the most money held offshore, according to a U.S. Public Interest Research Group report issued last month.
McKesson agrees to pony up more than $2 billion for medical supplies provider PSS World Medical.
McKesson (NYSE:MCK) agreed to pay $29 per share for PSS World Medical (NSDQ:PSSI) and its medical supplies business in a deal worth $2.1 billion.
Medical device company Abiomed says the chances are slim that Medicare will grant a national coverage decision for its Impella heart pump.
Abiomed (NSDQ:ABMD) said it doesn't believe that the Centers for Medicare & Medicaid Services is likely to bestow a national coverage decision for its Impella heart pump.
Former McKesson Corp. chairman & CEO Charles McCall fails to pass muster with the U.S. Supreme Court, which rejected his bid for an appeal to reconsider his 10-year prison sentence tied to a conviction for an accounting scandal.
The Supreme Court refused to review the conviction of former McKesson (NYSE:MCK) chairman & CEO Charles McCall in an accounting scandal, meaning his 10-year prison sentence will stand.
The high court provided no comment on the denial. San Francisco, Calif.-based McKesson is the largest drug distributor in the U.S., and also deals in healthcare information technology products.